Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer with an EGFR mutation.
- Your cancer must be stage 3 (IIIA, IIIB, or IIIC) and not removable by immediate surgery.
- You must not have had any previous systemic cancer treatment.
- You must have good lung function and be able to tolerate surgery.
- You must be 18 years or older and have an ECOG performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests two drugs given before surgery to shrink tumors in people with a type of lung cancer (non-small cell) that has a specific protein called PD-L1. The goal is to see if this treatment helps remove the cancer more effectively.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
Hear when a new EGFR-mutant Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.